Camrelizumab+Fluzoparib

Phase 2

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

JHPCYPhase 2$38.2B

Camrelizumab+Fluzoparib Phase 2 Est. Readout

Camrelizumab+Fluzoparib• Germline BRCA-mutated HER2-negative Breast Cancer64

Q2 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in Germline BRCA-mutated HER2-negative Breast Cancer

View Full Landscape

Drug Information

Target Indication

Germline BRCA-mutated HER2-negative Breast Cancer

Clinical Trial

NCT05576389

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

JSKN003Phase 3

Advanced Solid Tumor

Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

RocuroniumPhase 3

Neuromuscular Blockade

HRS-9190Phase 3

Neuromuscular Blockade

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts